• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

No additive effects of peginterferon on the short-term improvement of liver histology by entecavir monotherapy in chronic hepatitis B patients.

作者信息

Kanda Tatsuo

机构信息

Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchi-kamicho, Itabashi-ku, Tokyo, 173-8610, Japan.

出版信息

Hepatol Int. 2021 Jun;15(3):579-581. doi: 10.1007/s12072-021-10191-w. Epub 2021 Apr 26.

DOI:10.1007/s12072-021-10191-w
PMID:33900575
Abstract
摘要

相似文献

1
No additive effects of peginterferon on the short-term improvement of liver histology by entecavir monotherapy in chronic hepatitis B patients.聚乙二醇干扰素对恩替卡韦单药治疗慢性乙型肝炎患者肝脏组织学短期改善无附加作用。
Hepatol Int. 2021 Jun;15(3):579-581. doi: 10.1007/s12072-021-10191-w. Epub 2021 Apr 26.
2
Early serum hepatitis B virus large surface protein level: a stronger predictor of virological response to peginterferon alfa-2a than that to entecavir in HBeAg-positive patients with chronic hepatitis B.早期血清乙型肝炎病毒大表面蛋白水平：与恩替卡韦相比，对 HBeAg 阳性慢性乙型肝炎患者聚乙二醇干扰素 alfa-2a 的抗病毒反应有更强的预测作用。
J Clin Virol. 2013 Aug;57(4):318-22. doi: 10.1016/j.jcv.2013.04.003. Epub 2013 Apr 29.
3
Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.在接受长期恩替卡韦治疗的HBeAg阳性慢性乙型肝炎患者中，聚乙二醇化干扰素序贯联合治疗可导致乙肝表面抗原消失和HBeAg血清学转换。
Antimicrob Agents Chemother. 2015 Jul;59(7):4121-8. doi: 10.1128/AAC.00249-15. Epub 2015 May 4.
4
Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON).聚乙二醇化干扰素α-2b联合核苷（酸）类似物治疗乙肝病毒e抗原阳性慢性乙型肝炎患者的随机对照试验（PEGON）
J Infect Dis. 2017 Apr 1;215(7):1085-1093. doi: 10.1093/infdis/jix024.
5
CD56 natural killer cells induce HBsAg reduction via cytolysis and cccDNA decay in long-term entecavir-treated patients switching to peginterferon alfa-2a.在长期接受恩替卡韦治疗后换用聚乙二醇干扰素α-2a的患者中，CD56自然杀伤细胞通过细胞溶解作用和共价闭合环状DNA降解诱导乙肝表面抗原减少。
J Viral Hepat. 2018 Nov;25(11):1352-1362. doi: 10.1111/jvh.12946. Epub 2018 Jul 10.
6
Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B.恩替卡韦和聚乙二醇干扰素序贯治疗慢性乙型肝炎年轻患者。
J Med Virol. 2016 Nov;88(11):1953-9. doi: 10.1002/jmv.24534. Epub 2016 Apr 18.
7
Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.使用聚乙二醇化干扰素-α2a作为一线治疗以及第12周乙肝病毒DNA/乙肝表面抗原停药规则对HBeAg阴性慢性乙型肝炎进行个体化治疗：一项成本效益分析
Antivir Ther. 2013;18(4):623-33. doi: 10.3851/IMP2555. Epub 2013 Mar 13.
8
Switching to peginterferon for chronic hepatitis B patients with hepatitis B e antigen seroconversion on entecavir - A prospective study.恩替卡韦治疗乙型肝炎 e 抗原血清学转换的慢性乙型肝炎患者换用聚乙二醇干扰素治疗的前瞻性研究。
J Viral Hepat. 2019 Jan;26(1):126-135. doi: 10.1111/jvh.13000. Epub 2018 Oct 18.
9
Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients?慢性乙型肝炎的最佳治疗：我应如何治疗我的 HBeAg 阴性患者？
Liver Int. 2015 Jan;35 Suppl 1:107-13. doi: 10.1111/liv.12717.
10
Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice.聚乙二醇干扰素联合恩替卡韦治疗对人源化小鼠细胞免疫无应答时血清乙型肝炎病毒标志物持续丢失。
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.00725-17. Print 2017 Sep.

本文引用的文献

1
Survival analysis between laparoscopic and open hepatectomy for hepatocellular carcinoma: a meta-analysis based on reconstructed time-to-event data.基于重建时间事件数据的腹腔镜与开腹肝切除术治疗肝细胞癌的生存分析：荟萃分析。
Hepatol Int. 2021 Oct;15(5):1215-1235. doi: 10.1007/s12072-021-10219-1. Epub 2021 Jul 13.
2
Leukocyte cell-derived chemotaxin 2 promotes the development of nonalcoholic fatty liver disease through STAT-1 pathway in mice.白细胞衍生趋化因子2通过STAT-1通路促进小鼠非酒精性脂肪性肝病的发展。
Liver Int. 2021 Apr;41(4):777-787. doi: 10.1111/liv.14816. Epub 2021 Feb 23.
3
Pilot study of tenofovir disoproxil fumarate and pegylated interferon-alpha 2a add-on therapy in Japanese patients with chronic hepatitis B.
富马酸替诺福韦二吡呋酯和聚乙二醇干扰素-α2a 联合治疗日本慢性乙型肝炎患者的初步研究。
J Gastroenterol. 2020 Oct;55(10):977-989. doi: 10.1007/s00535-020-01707-6. Epub 2020 Jul 14.
4
Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission.亚太地区的肝脏疾病：《柳叶刀·胃肠病学和肝脏病学》专刊。
Lancet Gastroenterol Hepatol. 2020 Feb;5(2):167-228. doi: 10.1016/S2468-1253(19)30342-5. Epub 2019 Dec 15.
5
Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot study.在HBe抗原阴性慢性乙型肝炎患者中，序贯联合聚乙二醇干扰素与核苷/核苷酸类似物治疗相比，降低乙肝表面抗原的疗效：一项初步研究。
Antivir Ther. 2018;23(8):639-646. doi: 10.3851/IMP3240.
6
Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBeAg-positive chronic hepatitis B: A five-year observational cohort study.聚乙二醇干扰素在预防HBeAg阳性慢性乙型肝炎患者不良事件方面优于恩替卡韦：一项五年观察性队列研究。
J Viral Hepat. 2017 Nov;24 Suppl 1:12-20. doi: 10.1111/jvh.12755.
7
Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection.核苷初治慢性乙型肝炎日本患者长期使用恩替卡韦。
J Hepatol. 2010 Jun;52(6):791-9. doi: 10.1016/j.jhep.2009.12.036. Epub 2010 Mar 24.
8
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.聚乙二醇干扰素α-2a、拉米夫定及两者联合治疗HBeAg阳性慢性乙型肝炎
N Engl J Med. 2005 Jun 30;352(26):2682-95. doi: 10.1056/NEJMoa043470.
9
Lamivudine for patients with chronic hepatitis B and advanced liver disease.拉米夫定用于慢性乙型肝炎和晚期肝病患者。
N Engl J Med. 2004 Oct 7;351(15):1521-31. doi: 10.1056/NEJMoa033364.